Lixte Biotechnology Holdings, Inc.

NasdaqCM:LIXT

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 2.12 M

Share Price

USD 0.71

Avg Daily Volume

19,736

Change (1 day)

-7.20%

Change (1 year)

-69.85%

Change (YTD)

-64.80%

Lixte Biotechnology Holdings, Inc. Market Capitalization on June 27, 2025: USD 2.12 M

Lixte Biotechnology Holdings, Inc. Market Capitalization is USD 2.12 M on June 27, 2025, a -60.18% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Lixte Biotechnology Holdings, Inc. 52-week low Market Capitalization is USD 7.73 M on June 27, 2025, which is 264.16% above the current Market Capitalization.
Lixte Biotechnology Holdings, Inc. 52-week low Market Capitalization is USD 2.12 M on June 27, 2025, which is 0.00% below the current Market Capitalization.
Lixte Biotechnology Holdings, Inc. average Market Capitalization for the last 52 weeks is USD 4.22 M.

Daily

From:

To:

Zoom:

Key data

Date	Market Capitalization	Share Price	Share Price	Price to Earnings Ratio (P/E)

NasdaqCM: LIXT

Lixte Biotechnology Holdings, Inc.

CEO	Mr. Bastiaan van der Baan M.Sc.
IPO Date	Oct. 25, 2007
Location	United States
Headquarters	680 East Colorado Boulevard
Employees	2
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.